

Communication to Stakeholders

June 2023

BROAD-BASED BLACK ECONOMIC EMPOWERMENT POLICY FOR ISSUANCE OF LICENCES AS PER SECTION 22C OF THE MEDICINES ACT

SAHPRA is a statutory body established in terms of section 2 of the Medicines and Related Substances Act (Act 101 of 1965), as amended, hereafter referred to as the “Medicines Act”, to provide for the monitoring, evaluation, regulation, investigation, inspection, registration, and control of health products, scheduled substances, clinical trials and related matters in the public interest.

SAHPRA as an organ of state and a public entity is required to align itself to the provisions of Section 10 (1) of the Broad-Based Black Economic Empowerment (“B-BBEE Act”). In order to be comply with requirements of the B-BBEE Act, SAHPRA has developed a B-BBEE Policy which intends to integrate all the elements of B-BBEE Act into the Authority’s function of issuing new and the renewal of licenses to manufacture, wholesale, distribute or import and export health products as well as the permits as envisaged in section 22C of Medicines Act.

Stakeholders are hereby invited to provide comments to the draft SAHPRA’s Broad-Based Black Economic Empowerment Policy for issuance of new and the renewal of licences as per section 22C of the Medicines Act.

Attached herewith is the SAHPRA draft Broad-Based Black Economic Empowerment Policy for issuance of new and the renewal of licences in terms of section 22C of the Medicines Act .

Submissions should be directed to SAHPRA using the following **link:** <https://forms.office.com/r/UNrNHU4C93> and **form attached (use both)**. The closing date for the online submission is on or before the end of business on **31st of August 2023**.

DR B SEMETE-MAKOKOTLELA

SAHPRA CHIEF EXECUTIVE OFFICER

DATE: 22 JUNE 2023